Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.

ABSTRACT:

Background

The objective of this study was to evaluate trends in survival and health care costs in metastatic melanoma in the era of targeted and immunotherapeutic drugs.

Materials and methods

Data on survival and health care resource use were retrieved from the Dutch Melanoma Treatment Registry. The Kaplan-Meier method was used to estimate overall survival. Health care costs and budget impact were computed by applying unit costs to individual patient resource use. All outcomes were stratified by year of diagnosis.

Results

Baseline characteristics were balanced across cohort years. The percentage of patients receiving systemic treatment increased from 73% in 2013 to 90% in 2018. Patients received on average 1.85 [standard deviation (SD): 1.14] lines of treatment and 4

SUBMITTER: Franken MG 

PROVIDER: S-EPMC8639434 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature